Mirum Pharmaceuticals reports a wider-than-expected GAAP loss per share but exceeds revenue forecasts for the quarter.
Mirum Pharmaceuticals posted a GAAP loss per share of $13.43, missing estimates by $13.06. The company’s quarterly revenue reached $159.9M, surpassing expectations by $11.69M.
Analysts had anticipated a narrower loss and lower revenue for the period. The revenue beat reflects stronger-than-expected demand for the company’s treatments, while the EPS miss highlights ongoing cost pressures.
Shares may face volatility as investors weigh the mixed results against broader sector trends.